Medicago Announces Production of a Viable Vaccine Candidate for COVID-19
Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that they have successfully produced a Virus-Like Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of the VLP is the first step in developing a vaccine for COVID-19, which will now undergo preclinical testing for safety and efficacy. Once this is completed, Medicago expects to discuss with the appropriate Health Agencies to initiate human trials of the vaccine by summer (July/August) 2020.
Medicago is also using its technology platform to develop antibodies against SARS-CoV-2 in collaboration with the Laval University’s Infectious Disease Research Centre headed by Dr. Gary Kobinger, who helped develop a vaccine and treatment for Ebola. These SARS-CoV-2 antibodies could potentially be used to treat people infected by the virus. This research is being funded, in part, by the Canadian Institutes for Health Research (CIHR).
Medicago is a leader in plant-based technology, having previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
“The pace of our initial progress in COVID-19 is attributable to the capability of our plant-based platform, which is able to produce vaccine and antibody solutions to counteract this global public health threat. The ability to produce a candidate vaccine within 20 days after obtaining the gene is a critical differentiator for our proven technology. This technology enables scale-up at unprecedented speed to potentially combat COVID-19,” said Dr. Bruce Clark, CEO of Medicago.
Dr. Gary Kobinger, Professor in the Department of Microbiology and Infectious Diseases and the Director of the Infectious Disease Research Centre at Laval University, said “The collaborative efforts established between the research team at Laval University and Medicago have been very successful in developing unique antibodies against infectious diseases such as RSV and HMPV, and that experience gives us confidence for successful identification of therapeutic antibodies against SARS-CoV-2.”
Medicago’s first product, a seasonal recombinant quadrivalent VLP vaccine for active immunization against influenza, is currently under review by Health Canada following the completion of a robust safety and efficacy clinical program involving over 25,000 patients.
Notes to Editors:
Medicago’s unique plant-based platform
The company uses a proprietary plant-based technology to develop protein-based therapeutics. Unlike traditional vaccination development, Medicago does not use animal products or live viruses to create its products. Instead, it uses Virus-Like Particles (VLPs) that mimic the shape and dimensions of a virus, which allows the body to recognize them and create an immune response in a non-infectious way. Clinical trial data suggest that VLPs have a multi-modal mechanism of action that is different from that of inactivated vaccines, activating both arms of the immune system – antibody and cell-mediated responses.
Medicago’s proprietary technology is rapid, versatile, and scalable. As soon as the genetic sequence of a virus is made available, Medicago can develop a clinical-grade vaccine candidate in only a few weeks. Its recombinant technology allows the production of a vaccine that precisely matches the circulating strains, such as in the case of seasonal influenza. The technology is easily scalable, allowing the company to increase volume of production by simply increasing the number of plants it uses.
Product portfolio and pipeline
Medicago’s first product, a Recombinant Quadrivalent Virus-Like Particle (QVLP) seasonal flu vaccine, is presently under review by Health Canada. Vaccine candidates for pandemic flu, rotavirus and norovirus are being tested across pre-clinical and Phase II clinical trials. Medicago is also developing antibodies against hMPV, RSV and Opioids.
Medicago is headquartered in Quebec City, Canada, and plans to produce COVID-19 vaccines and antibodies in its Quebec pilot plant to respond to the immediate short-term demand. The company also has a manufacturing facility in Durham, North Carolina (USA), which is currently dedicated to the production of vaccines and antibodies for its clinical trials and is expected to support the launch of the quadrivalent VLP influenza vaccine once it is approved. A new state-of-the-art manufacturing plant is under construction in Quebec City, which will be fully functional by 2023 and will have the capability to deliver up to 50 million doses of recombinant quadrivalent influenza vaccine per year.
Medicago is a biopharmaceutical company with more than 450 employees in Canada and the United States. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide.
For more information: www.medicago.com
English media contact:
Alissa Von Bargen
French media contact:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Group Opens Singapore Office8.7.2020 02:00:00 CEST | Press release
Interactive Brokers Group (Nasdaq: IBKR), a global brokerage firm, today announced the addition of a Singapore entity Interactive Brokers Singapore Pte Ltd and the opening of an office located in the Marina Bay Financial District. With the addition of Singapore, the global brokerage firm now has nine entities around the globe in the US, Australia, Canada, Hong Kong, India, Japan, Luxembourg and the UK, serving over 876,000 clients accounts in more than 220 countries and territories. “As our client base continues to rapidly increase in Singapore, it was important to create a presence on the ground to support and service active traders and the wealth management community,” said David Friedland, Managing Director of the Asia Pacific region for Interactive Brokers. “As a critical wealth management and financial hub in Asia, our expansion in the region reflects that importance and keeps up with account growth.” Over 37% of Interactive Brokers accounts now come from Asia, up from 27% in 2017
Mary Kay Inc. Continues Its Support of Beauty, Fashion, and Design in Events Held Across Asia, Europe and the U.S.8.7.2020 00:10:00 CEST | Press release
Mary Kay Inc. and its Mary Kay Global Design Studio, recently sponsored and participated in various beauty, fashion and design events around the world with the aim of promoting the art of individual and unique beauty—and beauty artists themselves—setting the stage for the upcoming trends for the season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005913/en/ Mary Kay beauty experts were on hand to tailor looks before the 27th Czech Lion Awards Show (Photo: Mary Kay) Glamhive Live & Glamhive Digital Summer Bazaar Mary Kay was the presenting sponsor for the inaugural Glamhive Live Digital Summit on May 9. Glamhive, a startup digital fashion company founded by celebrity stylist Stephanie Sprangers, allows users to receive straight-forward virtual advice from expert stylists around the world. Glamhive stylists include Tara Swennen, Ilaria Urbinati, Nicole Chavez, Jeanne Yang, Samantha McMillen, Sonia Young, Micah Schifma
FDA Authorizes Marketing of IQOS as a Modified Risk Tobacco Product7.7.2020 20:47:00 CEST | Press release
Regulatory News: The U.S. Food and Drug Administration (FDA) today authorized the marketing of IQOS, Philip Morris International’s (PMI) electrically heated tobacco system, as a modified risk tobacco product (MRTP). In doing so, the agency found that an IQOS exposure modification order is appropriate to promote the public health. - Today’s decision demonstrates that IQOS is a fundamentally different tobacco product and a better choice for adults who would otherwise continue smoking - IQOS is the first and only electronic nicotine product to be granted marketing orders through the FDA’s MRTP process - The FDA authorized the marketing of IQOS with the following information: - The IQOS System heats tobacco but does not burn it - This significantly reduces the production of harmful and potentially harmful chemicals - Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system reduces your body’s exposure to harmful or potentially harmful chemical
Interactive Brokers Group to Host Second Quarter Earnings Conference Call7.7.2020 15:00:00 CEST | Press release
Interactive Brokers Group, Inc. (Nasdaq: IBKR) plans to announce its second quarter financial results on Tuesday, July 21, 2020, in a release that will be issued at approximately 4:00 pm (ET). The press release will also be available on the company's website, www.interactivebrokers.com/ir. A conference call to discuss the company's results will be held at 4:30 pm (ET) on that day, July 21. Members of the public who would like to listen to the conference call should dial 877-324-1965 (U.S. domestic) or 631-291-4512 (international). The number should be dialed approximately ten minutes prior to the start of the conference call. The conference call will also be accessible as an audio webcast through the Investor Relations section of the Interactive Brokers website, www.interactivebrokers.com/ir. About Interactive Brokers Group, Inc.: Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 1
Virtual Esri User Conference to Explore How GIS Interconnects the World7.7.2020 14:41:00 CEST | Press release
Esri, the global leader in location intelligence, today announced that the 40th annual Esri User Conference will be the largest virtual gathering of GIS professionals. Normally held in San Diego, California, the conference will be presented in a completely virtual format and take place July 13–16, 2020. The Esri User Conference brings together technology innovators, executives, educators, scientists, and GIS users seeking to solve challenges in their organizations and throughout the world, using the most powerful mapping and analytics platform on the planet. This year's conference theme, GIS—Interconnecting Our World, explores how geospatial technology can integrate everything and engage everyone to overcome unprecedented global challenges. Esri founder and president Jack Dangermond will open the conference—which this year will see the Plenary Session span across three days—with his observations on how GIS, the world's nervous system, has never been more interconnected than it is today
Shippeo Extends Paperless Transportation and Advanced Pallet Scanning Capabilities to Its Real-Time Visibility Platform7.7.2020 14:18:00 CEST | Press release
Shippeo, the European leader in real-time transportation visibility solutions, has announced a new mobile application, offering a range of new capabilities. Shippeo’s mobile application allows truck drivers to manage electronic Bill of Lading via smartphone quickly and easily, unlocking the benefits of paperless administration. These include instant synchronisation with TMS for faster billing while also reducing administrative cost. In addition, electronic forms avoid paper handling, reducing hygiene concerns amid the Covid-19 pandemic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005487/en/ Shippeo mobile application (Photo: Shippeo) The new Shippeo mobile application features include: Paperless proof of delivery for last mile The mobile app integrates the generation of electronic Bills of Lading (or eCMRs) capturing electronic signatures and enabling paperless proof of delivery and fasting invoicing. Delivery perso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom